HRP20170734T1 - Povećana biodostupnost lijeka u terapiji naltreksonom - Google Patents

Povećana biodostupnost lijeka u terapiji naltreksonom Download PDF

Info

Publication number
HRP20170734T1
HRP20170734T1 HRP20170734TT HRP20170734T HRP20170734T1 HR P20170734 T1 HRP20170734 T1 HR P20170734T1 HR P20170734T T HRP20170734T T HR P20170734TT HR P20170734 T HRP20170734 T HR P20170734T HR P20170734 T1 HRP20170734 T1 HR P20170734T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
naltrexone
bupropion
use according
Prior art date
Application number
HRP20170734TT
Other languages
English (en)
Croatian (hr)
Inventor
Shawn Flanagan
Eduardo Dunayevich
Original Assignee
Orexigen Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170734(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics, Inc. filed Critical Orexigen Therapeutics, Inc.
Publication of HRP20170734T1 publication Critical patent/HRP20170734T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HRP20170734TT 2010-12-03 2011-12-02 Povećana biodostupnost lijeka u terapiji naltreksonom HRP20170734T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03
EP11845186.3A EP2646031B9 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy
PCT/US2011/063177 WO2012075459A1 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy

Publications (1)

Publication Number Publication Date
HRP20170734T1 true HRP20170734T1 (hr) 2017-08-11

Family

ID=46172304

Family Applications (4)

Application Number Title Priority Date Filing Date
HRP20170734TT HRP20170734T1 (hr) 2010-12-03 2011-12-02 Povećana biodostupnost lijeka u terapiji naltreksonom
HRP20240115TT HRP20240115T1 (hr) 2010-12-03 2011-12-02 Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
HRP20251576TT HRP20251576T1 (hr) 2010-12-03 2011-12-02 Povećanje bioraspoloživosti lijekova u terapiji naltreksonom
HRP20210618TT HRP20210618T1 (hr) 2010-12-03 2021-04-19 Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom

Family Applications After (3)

Application Number Title Priority Date Filing Date
HRP20240115TT HRP20240115T1 (hr) 2010-12-03 2011-12-02 Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
HRP20251576TT HRP20251576T1 (hr) 2010-12-03 2011-12-02 Povećanje bioraspoloživosti lijekova u terapiji naltreksonom
HRP20210618TT HRP20210618T1 (hr) 2010-12-03 2021-04-19 Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom

Country Status (27)

Country Link
US (1) US20130245056A1 (enExample)
EP (5) EP2646031B9 (enExample)
JP (5) JP6008866B2 (enExample)
KR (5) KR20140035320A (enExample)
CN (1) CN103313711A (enExample)
AR (2) AR093182A1 (enExample)
AU (2) AU2011336304B2 (enExample)
BR (1) BR112013013390A2 (enExample)
CA (2) CA3239386A1 (enExample)
CL (1) CL2013001564A1 (enExample)
CY (2) CY1118968T1 (enExample)
DK (4) DK4349369T3 (enExample)
ES (3) ES2866879T3 (enExample)
FI (2) FI3884947T3 (enExample)
HR (4) HRP20170734T1 (enExample)
HU (3) HUE065852T2 (enExample)
IL (3) IL226504B (enExample)
LT (4) LT2646031T (enExample)
MX (2) MX384662B (enExample)
PL (4) PL3222280T3 (enExample)
PT (4) PT3884947T (enExample)
RS (4) RS65198B1 (enExample)
RU (1) RU2640561C2 (enExample)
SI (4) SI3884947T1 (enExample)
SM (4) SMT202100227T1 (enExample)
TW (1) TWI618536B (enExample)
WO (1) WO2012075459A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
PL3222280T3 (pl) * 2010-12-03 2021-11-29 Nalpropion Pharmaceuticals Llc Wzrost biodostępności leku w terapii naltreksonem
HUE072188T2 (hu) 2012-06-06 2025-10-28 Nalpropion Pharmaceuticals Llc Készítmény magas kardiovaszkuláris kockázatú túlsúlyos és elhízott páciensek kezelésére szolgáló eljárásban történõ alkalmazásra
WO2016125109A1 (en) * 2015-02-07 2016-08-11 Intas Pharmaceuticals Ltd. Pharmaceutical composition for the treatment of obesity
EP3600433B1 (en) * 2017-03-28 2021-05-05 LDN Pharma Limited An agent that increases the expresssion of the bcl2-associated agonist of cell death for the treatment of cancer
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
US12303604B1 (en) * 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
WO2004096201A1 (en) * 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2007016108A1 (en) 2005-07-27 2007-02-08 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
WO2007089318A2 (en) 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US20070179168A1 (en) 2005-11-28 2007-08-02 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR101486228B1 (ko) * 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
KR101264789B1 (ko) * 2006-06-30 2013-05-15 엘지디스플레이 주식회사 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
WO2008011150A1 (en) * 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
KR20150082689A (ko) 2006-11-09 2015-07-15 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
SI3461503T1 (sl) * 2007-04-11 2022-04-29 Biomarin Pharmaceutical Inc. Postopki za dajanje tetrahidrobiopterina, povezani sestavki in postopki merjenja
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
PL3222280T3 (pl) 2010-12-03 2021-11-29 Nalpropion Pharmaceuticals Llc Wzrost biodostępności leku w terapii naltreksonem

Also Published As

Publication number Publication date
JP2019056004A (ja) 2019-04-11
TW201304780A (zh) 2013-02-01
FI4349369T3 (fi) 2025-12-17
SMT201700232T1 (it) 2017-07-18
IL279626A (en) 2021-03-01
KR101984500B1 (ko) 2019-05-31
EP3884947A1 (en) 2021-09-29
FI3884947T3 (fi) 2024-01-30
JP2024071605A (ja) 2024-05-24
US20130245056A1 (en) 2013-09-19
EP4349369B1 (en) 2025-09-17
DK4349369T3 (da) 2025-12-22
RU2013127423A (ru) 2015-01-10
ES3056642T3 (en) 2026-02-23
ES2625527T9 (es) 2018-09-25
HRP20251576T1 (hr) 2026-01-30
DK3222280T3 (da) 2021-04-19
AU2011336304B2 (en) 2017-03-30
EP2646031B9 (en) 2018-01-10
PL3222280T3 (pl) 2021-11-29
JP2022060331A (ja) 2022-04-14
ES2625527T3 (es) 2017-07-19
KR20140035320A (ko) 2014-03-21
KR102105857B1 (ko) 2020-05-04
HUE053831T2 (hu) 2021-07-28
KR20180069089A (ko) 2018-06-22
MX384662B (es) 2025-03-14
KR20200044158A (ko) 2020-04-28
IL226504B (en) 2021-01-31
HUE034393T2 (en) 2018-02-28
EP3222280A1 (en) 2017-09-27
AR124500A2 (es) 2023-04-05
IL270841A (en) 2020-01-30
JP6008866B2 (ja) 2016-10-19
CY1124331T1 (el) 2022-07-22
CY1118968T1 (el) 2018-01-10
PT2646031T (pt) 2017-05-25
KR102258043B1 (ko) 2021-05-28
KR102391511B1 (ko) 2022-04-26
DK2646031T3 (en) 2017-05-22
RU2640561C2 (ru) 2018-01-09
HRP20210618T1 (hr) 2021-09-17
AU2011336304A1 (en) 2013-07-11
LT3884947T (lt) 2024-03-12
BR112013013390A2 (pt) 2016-09-06
CA2819262A1 (en) 2012-06-07
JP6456890B2 (ja) 2019-01-23
KR20190058702A (ko) 2019-05-29
EP3884947B1 (en) 2023-11-15
CA3239386A1 (en) 2012-06-07
EP4349369A2 (en) 2024-04-10
AU2017204309A1 (en) 2017-07-13
PL3884947T3 (pl) 2024-05-06
SI3222280T1 (sl) 2021-11-30
EP4696322A2 (en) 2026-02-18
CN103313711A (zh) 2013-09-18
EP4696322A3 (en) 2026-04-15
PL4349369T3 (pl) 2026-03-23
EP3222280B1 (en) 2021-01-20
RU2017144631A3 (enExample) 2021-04-13
TWI618536B (zh) 2018-03-21
AR093182A1 (es) 2015-05-27
CA2819262C (en) 2024-05-28
HRP20240115T1 (hr) 2024-06-07
JP7025319B2 (ja) 2022-02-24
MX356801B (es) 2018-06-13
RS67527B1 (sr) 2026-01-30
EP2646031A4 (en) 2014-04-23
PL2646031T3 (pl) 2017-08-31
RS56014B1 (sr) 2017-09-29
PT3222280T (pt) 2021-04-22
SMT202500474T1 (it) 2026-01-12
MX2013006071A (es) 2013-10-01
RS65198B1 (sr) 2024-03-29
SI3884947T1 (sl) 2024-06-28
RU2017144631A (ru) 2019-02-18
PT4349369T (pt) 2025-12-17
SMT202400038T1 (it) 2024-03-13
SMT202100227T1 (it) 2021-07-12
LT3222280T (lt) 2021-05-10
EP4349369A3 (en) 2024-05-15
SI2646031T1 (sl) 2017-07-31
WO2012075459A1 (en) 2012-06-07
KR20210063473A (ko) 2021-06-01
LT2646031T (lt) 2017-06-26
JP2016210809A (ja) 2016-12-15
DK3884947T3 (da) 2024-01-22
EP2646031B1 (en) 2017-02-22
HUE065852T2 (hu) 2024-06-28
EP2646031A1 (en) 2013-10-09
LT4349369T (lt) 2026-01-12
SI4349369T1 (sl) 2026-02-27
JP2013544290A (ja) 2013-12-12
RS62149B1 (sr) 2021-08-31
PT3884947T (pt) 2024-02-16
ES2866879T3 (es) 2021-10-20
CL2013001564A1 (es) 2014-05-02

Similar Documents

Publication Publication Date Title
HRP20210618T1 (hr) Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
AU2023200826B2 (en) Administration of berberine metabolites
JP2013544290A5 (enExample)
HRP20210239T1 (hr) Tetrahidrobiopterin za liječenje stanja povezanih s povišenim razinama fenilalanina
MX2015011896A (es) Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia.
JP2009525343A5 (enExample)
HRP20171743T1 (hr) Sastavi i postupci za savladavanje otpornosti na tramadol
HRP20240121T1 (hr) Kontracepcija na bazi drospirenona za pacijenticu s viškom tjelesne težine
HRP20250615T1 (hr) Tradipitant za upotrebu u liječenju gastropareze
JP2015038135A5 (enExample)
JP2013516493A5 (enExample)
WO2007123865A3 (en) Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
JP2017525771A (ja) 体重と体脂肪減少に用いられる組成物およびその医薬品と使用
JP2011510922A5 (enExample)
JP2007238598A5 (enExample)
WO2011019735A3 (en) Nutritional supplements
JP2013540133A5 (enExample)
JP2015501849A5 (enExample)
CN103919774A (zh) 去亚甲基小檗碱在制备降血脂药物中的应用
CN103491959A (zh) Trmp5抑制剂在不减少食物摄入时支持体重减轻
CN203123076U (zh) 替米沙坦氨氯地平片
RU2009145804A (ru) Аксомадол для лечения боли от артроза
KR20190134671A (ko) 체중을 감소시키고 체지방을 감소시키기 위한 조성물 및 그의 제약 생성물 및 적용
JP2010090097A (ja) 抗骨粗鬆症組成物
WO2011108882A3 (ko) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물